Biomarker development for cancer personalized medicine through proteomic analysis

January 1, 2026Electrophoresis LettersOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to develop biomarkers for cancer personalized medicine using proteomic analysis.
Utilized fluorescent two-dimensional electrophoresis for high-sensitivity proteome analysis.
Integrated large datasets with clinical information using machine learning techniques.
Collaborated with young clinical doctors on various types of cancers including lung and gastric cancer.
Established approximately 90 patient-derived cell lines and xenografts for sarcoma studies.
Achieved high sensitivity and reproducibility in proteomic analyses.
Developed a wealth of data supporting the validation of cancer biomarkers.
Contributed to advancements in personalized cancer treatment approaches.

Answers are grounded in this paper and cite their sources.

The study demonstrates the development of biomarkers in cancer personalized medicine, suggesting potential advancements in treatment strategies.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Tadashi Kondo (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share